Population pharmacokinetics of cisapride in neonates

European Journal of Clinical Pharmacology

Volumn 58, Issue 8, 2002, Pages 507-513

  Odoul, F ^a   Le Guellec, C ^a,d   Henrot, A ^a   Saliba, E ^a   Levron, J C ^b   Saux, M C ^c   Paintaud, G ^a   Autret Leca, E ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b Janssen Cilag   (France)

^c PESSAC   (France)

^d CHU BRETONNEAU   (France)

Author keywords

Cisapride; Gastro oesophageal reflux disease; Neonate; Pharmacokinetics

Indexed keywords

CISAPRIDE;

ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION ANALYSIS; COVARIANCE; DATA ANALYSIS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMATURITY; INFANT; MALE; NEWBORN; PERINATAL PERIOD; POPULATION RESEARCH; PREMATURITY; PRIORITY JOURNAL; WEIGHT;

CISAPRIDE; FEMALE; HUMANS; INFANT, NEWBORN; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES;

EID: 0036452964     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0504-z     Document Type: Article

References (35)

1. Vandenplas Y (1998) Clinical use of cisapride and its risk benefit in paediatric patients. Eur J Gastroenterol Hepatol 10:871-881
2. Wysowski DK, Bacsanyi J (1996) Cisapride and fatal arrhythmia. N Engl J Med 335:290-291
3. Ahmad SR, Wolfe SM (1995) Cisapride and torsade de pointes. Lancet 345:508
4. Lewin MB, Bryant RM, Fenrich AL et al (1996) Cisapride-induced long QT interval. J Pediatr 128:279-281
5. Pettignano R, Chambliss R, Darsey E, Heard M, Clark R (1996) Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support. Crit Care Med 24:1268-1271
6. Faure C, Bedu A, Lupoglazoff JM et al (1996) Allongement de l'Espace QT sous Cisapride chez le Nouveau né et le Nourrisson. Groupe francophone d'hépatologie, gastroentérologie et nutrition pédiatriques. Nancy
7. Caley CF (1996) Cisapride interaction with antidepressants. Ann Pharmacother 30:684
8. Bedford TA, Rowbothamdt DT (1996) Cisapride - Drug interactions of clinical significance. Drug Saf 15:167-175
9. Vijgen J, Lukito G, Massa G et al (2000) Ranitidine and cisapride significantly prolong QTc interval in infants. Acta Cardiologica 55:143
10. Autret E, Jonville-Bera AP, Champel V (1997) La toxicité cardiaque du cisapride (Prepulsid) mérite d'être prise en compte dans sa prescription en particulier chez le prématuré. Arch Pediatr 4:507-508
11. Valdes L, Champel V, Olivier C, Jonville-Bera AP, Autret-Leca E (1997) Malaise avec allongement de l'espace QT chez un nourrisson de 39 jours associé à un traitement par cisapride. Arch Pediatr 4:535-537
12. Lupoglazoff JM, Bedu A, Faure C et al (1997) Allongement de l'espace QT sous cisapride chez le nouveau né et le nourrisson. Arch Pédiatr 4:509-514
13. Cools F, Benatar A, Feenstra A et al (2000) Cisapride plasma levels and QT duration in prematures. J Pediatr Gastroenterol Nutr 31 [Suppl 2]:S136
14. Vandenplas Y, Benatar A, Cools F, Arana A, Hegar B, Hauser B (2001) Efficacy and tolerability of cisapride in children. Paediatr Drugs 8:559-573
15. McCallum RW, PraKash C, Campoli-Richards DM et al (1988) Cisapride: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 36:652-681
16. Hatlebakk JG, Berstad A (1996) Pharmacokinetic optimisation in the treatment of gastrooesophageal reflux disease. Clin Pharmacokinet 31:386-406
17. Gross AS, Goh YD, Addison RS, Shenfield GM (1999) Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther 65:395-401
18. Kivistö KT, Lilja JJ, Backman JT et al (1999) Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 66:448-453
19. Whiting B, Kelman A, Grevel J (1986) Population pharmacokinetics: Theory and applications. Clin Pharmacokinet 11:387-401
20. Preechagoon Y, Charles B, Piotrovskij V, Donovan T, Van Peer A (1999) Population pharmacokinetics of enterally administered cisapride in young infants with gastrooesophageal reflux disease. Br J Clin Pharmacol 48:688-693
21. Van Haarst AD, Van't Klooster GAE, van Gerven JMA, Schoemaker RC, van Oene JC, Burgraaf J, Coene MC, Cohen AF (1998) The influence of cisapride and clarythromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 64:542-546
22. Vitola J, VuKanovic J, Roden DM (1998) Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol 9:1109-1113
23. Villain E, Kachaner J, Le Bidois J et al (1990) Bloc auriculoventriculaire et allongement de QT chez quatre prématurés recevant du diphémanil. Arch Fr Pediatr 47:33-35
24. Haycock GB, Schwartz GJ, Wisotsky DH (1978) Geometric method for measuring body surface area: height-weight formula validated in infants, children and adults. J Pediatr 93:62-66
25. Anderson BJ, Woollard GA, Holford NH (2000) A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 50:125-134
26. De Wilt SN, Kearns GL, Leeder S, van den Anker JN (1999) Cytochrome P4503A, ontogeny and drug disposition. Clin Pharmacokinet 37:485-505
27. Lee TC, Charles BG, Steer PA et al (1996) Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. Br J Clin Pharmacol 41:191-200
28. Falcao AC, Fernandez de Gratta MM, Delgado Iribarnegaray MF et al (1997) Population pharmacokinetics of caffeine in premature neonates. Eur J Clin 52:211-217
29. Pariente-Khayat A, Tréluyer JM, Rey E et al (1999) Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants. Clin Pharmacol Ther 66:136-139
30. Lauritsen K, Laursen LS, Rask-Madsen JR (1990) Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (part I). Clin Pharmacokinet 19:11-31
31. Lauritsen K, Laursen LS, Rask-Madsen JR (1990) Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (part II). Clin Pharmacokinet 19:94-125
32. Morgan DJ, Bray KM (1994) Lean body mass as a predictor of drug dosage: Implications for drug therapy. Clin Pharmacokinet 26:292-307
33. Gotschall RR, Marucci K, Leeder JS et al (1999) Cisapride biotransformation: not all CYP3A are equal. Clin Pharmacol Ther 65:127A
34. Treluyer JM, Rey E, Sonnier M, Pons G, Cresteil T (2001) Evidence of impaired cisapride metabolism in neonates. Br J Clin Pharmacol 52:419-25
35. Schuetz JD, Beach DL, Guzelian PS (1994) Selective expression of cytochrome P450 CYP3A mRNA in embryonic and adult human liver. Pharmacogenetics 4:11-20